Prescribing information



MDS is a group of stem-cell disorders characterised by ineffective haematopoiesis resulting in cytopenia, and potential progression to AML in a third of patients.1 They occur due to clonal mutations triggering the suppression of normal stem cell development.2 80% of MDS cases are idiopathic, but autoimmune disorders and exposure to radiotherapy, chemotherapeutic agents, toxic chemicals and viral infections can increase the risk of these mutations.1,2

The incidence of MDS is approximately 4.9 per 100,000,2 with risk increasing with age. Less than 10% of MDS patients are <50 years old;1 the median age at presentation is approximately 70–75 years,3 with a prevalence in males and caucasians.4

Box listing the types of MDS as classified by WHO
Box listing the common symptoms shared by different types of MDS

Bleeding and infections represent the most common cause of mortality,2 and the 3-year survival rate is approximately 60%.4

Treatment in high risk patients aims to avoid progression to AML using hypomethylating agents as first-line therapy. In low-risk patients, the focus is on the treatment of cytopenias such as anaemia, where high-dose erythropoiesis-stimulating agents are the first-line therapy.1 More than 80% of people with MDS experience anaemia and often require repeated RBC transfusions to manage their symptoms6

MDS and the risk of iron overload

Repeated transfusions can cause complications, and iron overload is an inevitable consequence for many patients with MDS.6


Abbreviations: AML, acute myeloid leukaemia; MDS, myelodysplastic syndromes; RBC, red blood cell.


  1. Adès L, et al. Myelodysplastic syndromes. Lancet 2014;383:2239–2252.
  2. Mohammad AA. Myelodysplastic syndrome from theoretical review to clinical application view. Oncol Rev 2018;12(397):134–142.
  3. Weinberg OK and Hasserjian RP. The current approach to the diagnosis of myelodysplastic syndromes. Sem Haem 2019;59:15–21.
  4. Goldberg S, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010;28(17):2847–2852.
  5. Martinez SFM, et al. Myelodysplastic syndrome clinically presenting with the “Classic TTP Pentad”. Case Reports in Hematology 2017:4619406.
  6. Balducci L. Transfusion independence in patients with myelodysplastic syndromes. Cancer 2005;106:2087–2094.
Rate this content: 
No votes yet
HCP20-C005p June 2020.


For more information, refer to the EXJADE® (deferasirox) Summary of Product Characteristics:

Legal Category: POM.

PVC/PVDC/Aluminium blisters. Unit packs containing 30 or 90 film-coated tablets or multipacks containing 300 (10 packs of 30) film-coated tablets. Not all pack sizes may be marketed. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/06/356/011 – 90 mg film-coated tablets 30 pack, £126.00. EU/1/06/356/014 – 180 mg film-coated tablets 30 pack, £252.00. EU/1/06/356/017 – 360 mg film-coated tablets 30 pack, £504.00 pack £1,540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2,310.



For more information, refer to the DESFERAL® (desferrioxamine mesilate) Summary of Product Characteristics:

Legal Category: POM.

Each vial contains a white to practically white lyophilisate supplied in a clear glass vial in a pack size of 10 (500 mg) or 1 (2 g). Marketing Authorisation (MA) number, quantities and NHS price: PL 00101/0523. Boxes of 10 £46.63.



Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]